PTC Therapeutics
Open
$65.28
Prev. Close
$65.27
High
$65.28
Low
$65.19
Market Snapshot
$5.18B
7.6
-4.73
$806.78M
991
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 991 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
PTC Therapeutics shares fell 9.08% to $63.88 amid rising concerns over potential FDA disapproval following disappointing interim study results for their clinical trials.
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 991 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Recently from Cashu
Jessica Chutter Joins PTC Therapeutics' Board to Enhance Strategic Vision and Growth
PTC Therapeutics Welcomes Jessica Chutter to Its Board of Directors PTC Therapeutics, Inc. recently announces the appointment of Jessica Chutter to its Board of Directors, aiming to bolster its strate…
PTC Therapeutics Enhances Employee Engagement with New Stock Options and RSUs Package
PTC Therapeutics Strengthens Employee Engagement with New Compensation Package On March 10, 2026, PTC Therapeutics, Inc. announces a significant step in employee engagement and retention as it grants…
PTC Therapeutics Boosts Talent Acquisition with Stock Options and RSUs for New Employees
PTC Therapeutics Enhances Talent Acquisition through Stock Options and RSUs PTC Therapeutics, Inc. announces a significant step in its human resources strategy with the approval of non-statutory stock…
UniQure Faces FDA Scrutiny Over Huntington's Gene Therapy Amid Controversy and Ethical Concerns
Navigating Controversy: UniQure's Gene Therapy for Huntington's Disease Under FDA Scrutiny UniQure is embroiled in a dispute with the U.S. Food and Drug Administration (FDA) regarding its gene therapy…